ReviewBioscience reports2026
Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.
Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is one of the most frequent and serious complications in cancer patients, contributing significantly to morbidity, mortality, and increased healthcare burden. Circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs), components of the liquid biopsy, have emerged not only as biomarkers of disease progression and therapeutic resistance but also as potential contributors to prothrombotic states in oncologic patients. In this review, we explore the biological and clinical relationships between CTCs/CTMs and the development of VTE, highlighting mechanistic insights involving tumor-platelet interactions, immune evasion, and endothelial dysfunction. We also discuss recent findings on the prognostic value of CTCs and CTMs for thromboembolic risk stratification, as well as technological advances in their detection. Understanding the role of these circulating tumor-derived elements may open new perspectives for personalized prevention and management of thromboembolic events in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.